Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Shares Outstanding (Weighted Average) (2016 - 2023)

Historic Shares Outstanding (Weighted Average) for Gyre Therapeutics (GYRE) over the last 15 years, with Q3 2023 value amounting to $38.0 million.

  • Gyre Therapeutics' Shares Outstanding (Weighted Average) rose 2062.03% to $38.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $38.0 million, marking a year-over-year increase of 2062.03%. This contributed to the annual value of $31.5 million for FY2022, which is 295.27% up from last year.
  • Latest data reveals that Gyre Therapeutics reported Shares Outstanding (Weighted Average) of $38.0 million as of Q3 2023, which was up 2062.03% from $37.8 million recorded in Q2 2023.
  • In the past 5 years, Gyre Therapeutics' Shares Outstanding (Weighted Average) registered a high of $38.0 million during Q3 2023, and its lowest value of $12.0 million during Q1 2019.
  • In the last 5 years, Gyre Therapeutics' Shares Outstanding (Weighted Average) had a median value of $31.0 million in 2021 and averaged $26.2 million.
  • In the last 5 years, Gyre Therapeutics' Shares Outstanding (Weighted Average) soared by 9452.13% in 2021 and then surged by 33.39% in 2022.
  • Over the past 5 years, Gyre Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $12.0 million in 2019, then surged by 59.53% to $19.2 million in 2020, then skyrocketed by 59.76% to $30.6 million in 2021, then grew by 2.95% to $31.5 million in 2022, then increased by 20.39% to $38.0 million in 2023.
  • Its Shares Outstanding (Weighted Average) was $38.0 million in Q3 2023, compared to $37.8 million in Q2 2023 and $37.8 million in Q1 2023.